NJ A 5359
in committeeClassifies 7 Hydroxymitragynine as Schedule I drug.
New Jersey · 222 · lower
Quick answers
Did NJ A 5359 pass?
Not yet. NJ A 5359 is in committee as of 2026-09-10 and has not come to a final vote. Latest recorded action (2026-09-10): Introduced, Referred to Assembly Judiciary Committee
What is NJ A 5359 about?
NJ A 5359 is a bill in the 222 titled “Classifies 7 Hydroxymitragynine as Schedule I drug.”.
Who sponsors NJ A 5359?
Inganamort, Michael is the primary sponsor of NJ A 5359.
- Introduced
- —
- Latest action
- 2026-09-10 — Introduced, Referred to Assembly Judiciary Committee
- Bill type
- bill
- Last updated
- —
Sponsors
- Inganamort, Michaelprimary
Committees
Not provided by source.
Action timeline
2026-09-10
Introduced, Referred to Assembly Judiciary Committee
introduction,referral-committee
Versions
- IntroducedCompare
Documents
Votes
Not provided by source.
Related bills
- Companion bill: S 301
Official source
Attribution
Data from openstates_api_sync, retrieved 2026-09-13T06:34:57.164819Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NJ&identifier=A 5359. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.